SOLIQUA 100/33 IS CLINICALLY PROVEN

SOLIQUA 100/33 is clinically proven to lower A1c. It combines two medicines that work together all day and all night along with diet and exercise to help control blood sugar. Whether you’re taking oral medications or an injectable [insulin] treatment, SOLIQUA 100/33 may be right for you. See our full study designs below to see how SOLIQUA 100/33 lowered A1c to below 7%.

For patients not at goal on up to 2 oral diabetes medications,
SOLIQUA 100/33 was proven to lower A1c below 7%

In a clinical study of patients with type 2 diabetes (Lixilan O), 74% of patients using SOLIQUA 100/33 lowered their A1c below 7%, while 59% of patients on Lantus® and 33% of patients on lixisenatide reached an A1c below 7%. The A1c average was reduced from a starting point of 8.1% to 6.5% in patients taking SOLIQUA 100/33, from 8.1% to 6.8% in patients taking Lantus, and from 8.1% to 7.3% in patients taking lixisenatide at the end of 30 weeks.

Your doctor may prescribe a dose of insulin that is different from the doses used in the study. The results seen in the trial may not reflect your results.

Individual results may vary.
The clinical study (Lixilan O) showed that in patients treated with metformin, SOLIQUA 100/33 improved blood sugar control compared to its individual components, a long-acting insulin (Lantus), and a non-insulin, diabetes medicine (lixisenatide). The study included 1,479 patients with type 2 diabetes who were on metformin alone or a 2nd oral diabetes medication which was subsequently discontinued and whose A1c was not at goal. After 4 weeks of taking metformin alone, during which time the metformin dose was optimized, 1,170 patients who had still not achieved their A1c goal with A1c 7-10%, had a fasting blood sugar ≤250 mg/dL, and were on ≥1500 mg metformin continued in the study. For the next 30 weeks patients continued taking metformin and were also treated with either SOLIQUA 100/33 (469 patients), Lantus (467 patients), or lixisenatide (234 patients). In the patients receiving insulin glargine 100 units/mL in the form of Lantus or SOLIQUA 100/33, the insulin glargine dose was adjusted in accordance with fasting self-monitored blood glucose measures aiming for a target of (80-100 mg/dL) with a dose cap of 60 units in both the Lantus and SOLIQUA 100/33 groups. The study showed that combining lixisenatide with Lantus in SOLIQUA 100/33 can help lower blood sugar even further than its individual components in patients taking metformin.

SOLIQUA 100/33 helps manage blood sugar all day and night

Managing your blood sugar along with diet and exercise is an important part of your diabetes treatment plan. SOLIQUA 100/33 may help by controlling blood sugar throughout the day and night.

For patients uncontrolled on long-acting insulin, SOLIQUA 100/33 was proven to lower A1c below 7%

In a different clinical study of patients with type 2 diabetes (Lixilan L), more than half (55%) of patients using SOLIQUA 100/33 lowered their A1c below 7%, versus 30% of patients using Lantus reached an A1c below 7%. On average, A1c was reduced from a starting point of 8.1% to 6.9% in patients taking SOLIQUA 100/33 and 8.1% to 7.5% in Lantus patients after 30 weeks of treatment. Patients using SOLIQUA 100/33 achieved almost twice (-1.1% vs -0.6%) the A1c reduction than patients who were using Lantus.§

Your doctor may prescribe a dose of insulin that is different from the doses used in the study. The differences between Lantus and SOLIQUA 100/33 seen in the trial may not reflect your results.

Individual results may vary.
§The clinical study (Lixilan L) showed how adding a non-insulin diabetes medicine (lixisenatide) to Lantus, a long-acting insulin, in a single injection improves blood sugar control, in patients uncontrolled on basal insulin with or without oral therapies. The study involved 1,018 patients with type 2 diabetes who had been taking a long-acting insulin for 6 months or more and up to 2 oral therapies, but had still not reached their A1c goal (<7%). After 6 weeks of starting and/or optimizing Lantus up to a dose of 50 units or less daily, discontinuing any oral therapy but metformin, achieving an A1c of 7-10%, with a fasting plasma glucose ≤140 mg/dL, 736 patients entered the study. For the next 30 weeks, half of the patients continued on Lantus and half were transitioned to SOLIQUA 100/33 (Lantus + non-insulin medicine). The study showed that combining lixisenatide with Lantus in the form of SOLIQUA 100/33 may help to lower blood sugar even further.

Pay as low as $0 with the CO-PAY Card

You may be eligible to pay $0 for the next 12 months!

Restrictions apply.*